Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Biotech Firms Bet Big on Oncology
The Biotechnology sector is placing a big bet on oncology. Throughout 2020, M&A in the Biotechnology sector has focused heavily on targets involving oncology research and products, both in deal volume and spending. Of the 97 Biotechnology deals reported through September 30, 26% involved oncology targets, with $37.25 billion in deal value, or 65% of the sector’s total announced spending, according to search results in our HealthCareMandA.com Deal Database. In the first three quarters of 2019, demand for oncology targets hit only 20% of deal volume, revealing an increased interest in 2020. Spending in 2019 for oncology targets and collaborations easily eclipsed the total this year,... Read More »
Molina Healthcare Acquires Affinity Health Plan
It has been an eventful year for Molina Healthcare (NYSE: MOH). With two acquisitions already on the books for 2020, the company has announced a third. Last week, Molina Healthcare purchased New York-based Affinity Health Plan for $380 million in cash, net of expected tax benefits. Affinity is a Medicaid managed care organization serving members in New York City, Westchester, Orange, Nassau, Suffolk and Rockland counties in New York. The organization currently has 284,000 members and premium revenues of $1.3 billion. The acquisition expands Molina’s market in New York and is immediately accretive to adjusted earnings per share. Molina Healthcare last announced a deal in July for... Read More »
Smith & Nephew Returns to the M&A Market
It’s been over a year since Smith & Nephew plc (NYSE: SNN) announced a transaction, but the medical device manufacturer is back on the acquisition trail. On September 29, the company purchased Integra LifeSciences Holdings Corporation’s (NASDAQ: IART) extremity orthopedics business for $240 million. The business includes a portfolio of devices, implants and instruments for shoulder replacement as well as reconstruction of bone in the hand, wrist and elbow, and foot and ankle. This deal will significantly strengthen Smith & Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities... Read More »
Bristol Myers Pumps up with MyoKardia
It’s been a busy year for Bristol Myers Squibb (NYSE: BMY) and its bankers. After two deals announced in 2020, the pharma giant is back for more with a $13.1 billion cash offer ($225 per share) for MyoKardia, Inc. (NASDAQ: MYOK). MyoKardia is a clinical-stage biopharmaceutical company focused on targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, Bristol Myers gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug Application for mavacamten is expected to be submitted to the U.S.... Read More »
Simplura Health Group Sells for $575 Million
The Home Health & Hospice sector had a jolt of activity last week. One Equity Partners is selling its portfolio company, Simplura Health Group, to The Providence Service Corporation (NASDAQ: PRSC) for $575 million. The Providence Service Corporation, through its wholly-owned subsidiary LogistiCare Solutions, LLC, is the nation’s largest manager of non-emergency medical transportation programs for state governments and managed care organizations. Providence Service Corporation is acquiring a 100% interest in Simplura. Simplura Health Group operates a large network of home health and personal care agencies across Connecticut, Florida, Massachusetts, New Jersey, New York,... Read More »
Health Care M&A Deals, October 2, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is AEW Capital Management’s purchase of a Welltower (NYSE: WELL) portfolio consisting of 10 seniors housing communities and 1,507 units located in California, Nevada and Washington. They were primarily independent living communities, with assisted living, memory care and multifamily units too. The purchase price was just over $700 million. To... Read More »
Ampersand Capital Partners Strikes Two Deals
Ampersand Capital Partners, a middle-market private equity firm, had a busy week, announcing two deals back to back. On September 21, the company revealed it acquired GeneWerk GmbH and American Laboratory Products Company, Ltd. for an undisclosed sum. Based in Heidelberg, Germany, GeneWerk GmbH is a cell and gene therapy testing laboratory focused on providing preclinical and clinical trial patient sample analysis services. The company is recognized as a leading provider of vector integration site analysis (ISA) services, a method that was developed by the company’s founders and that the FDA and European Medicines Agency recommend performing after the administration of both... Read More »
Adare Pharmaceuticals Sold to Two Private Equity Firms
Two private equity firms, Thomas H. Lee Partners and Frazier Healthcare Partners, are teaming up to acquire a leading specialty contract development and manufacturing organization (CDMO). The firms are buying Adare Pharmaceuticals. a global provider of advanced pharmaceutical technologies, development and manufacturing. The company utilizes its differentiated pharmaceutical technology and microbiome scientific platforms to develop novel, improved medicines and therapies for the global market. Adare has developed and manufactured more than 40 products sold by partners in more than 100 countries globally including Lacteol, Zoolac, Viactiv, and a number of branded and complex generic... Read More »
Illumina Acquires Cancer-Detection Company
Illumina (NASDAQ: ILMN) is making a big bet on the oncology market. The California-based company is acquiring GRAIL for $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL was founded by Illumina in 2016 and was spun out as a standalone company raising $2 billion. The company uses Illumina’s NGS technology to develop data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests. Illumina had already owned 14.5% of GRAIL before the deal, and Illumina stockholders are expected to own approximately 93% of the combined company, while GRAIL stockholders are expected to own... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
